Zoetis Inc. (NYSE:ZTS) Stock Now Rated “Hold” by Wall Street Brokerages

Zoetis Inc. (NYSE:ZTS) has been assigned a consensus rating of “Hold” from the nineteen ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $101.08.

A number of brokerages have weighed in on ZTS. Stifel Nicolaus cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. UBS Group reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Barclays dropped their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Finally, Zacks Research lowered Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ZTS. J. Stern & Co. LLP lifted its holdings in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares in the last quarter. BlackRock Inc. increased its holdings in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. State Street Corp increased its holdings in Zoetis by 1.8% during the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after acquiring an additional 343,322 shares during the period. Deutsche Bank AG lifted its stake in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after purchasing an additional 891,921 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Zoetis by 7.3% in the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after purchasing an additional 327,313 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $71.62 on Thursday. The stock has a market cap of $29.60 billion, a price-to-earnings ratio of 11.80, a PEG ratio of 1.66 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis has a fifty-two week low of $68.77 and a fifty-two week high of $148.30. The firm’s 50-day simple moving average is $74.03 and its 200 day simple moving average is $85.22.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the company earned $1.76 earnings per share. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts anticipate that Zoetis will post 6.2 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.